---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-25-000022"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:26:45.729472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025

## Summary
- Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.
- Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.
- R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.
- PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.
- PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation.

## SEC filing metadata
- accession: 0001728117-25-000022
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/0001728117-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-25-000022
- JSON: https://secwatch.observer/filing/0001728117-25-000022.json
- Plain text: https://secwatch.observer/filing/0001728117-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.